Altium Capital Management LLC Trims Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Altium Capital Management LLC trimmed its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 33.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 255,000 shares of the biopharmaceutical company's stock after selling 130,000 shares during the quarter. Catalyst Pharmaceuticals comprises approximately 1.5% of Altium Capital Management LLC's portfolio, making the stock its 25th biggest position. Altium Capital Management LLC owned approximately 0.21% of Catalyst Pharmaceuticals worth $5,322,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in CPRX. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. KBC Group NV grew its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $134,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CPRX shares. Robert W. Baird increased their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Finally, Stephens reiterated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Up 2.0 %

CPRX stock traded up $0.46 on Wednesday, reaching $23.06. 225,611 shares of the company's stock were exchanged, compared to its average volume of 1,107,345. The stock has a fifty day moving average of $22.58 and a 200-day moving average of $22.13. The firm has a market cap of $2.81 billion, a PE ratio of 19.54, a P/E/G ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.